Highlights Arno Therapeutics, Inc.

Equities

ARNI

US0425642032

Market Closed - OTC Markets Other stock markets 07:55:51 23/04/2024 pm IST			5-day change	1st Jan Change
0.0003 ^USD	+417.24%		-.--%	+200.00%

2017	Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University	CI
2017	Arno Therapeutics Seeks Acquisitions	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University	26/17/26	CI
Arno Therapeutics Seeks Acquisitions	04/17/04	CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	15/16/15	CI
Arno Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	23/16/23	CI
Arno Therapeutics, Inc. Updates Clinical Development of Onapristone Plus Zytiga	16/16/16	CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	18/16/18	CI
Arno Therapeutics, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2015	31/16/31	CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	17/15/17	CI
Arno Therapeutics, Inc. Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains	21/15/21	CI
Arno Therapeutics, Inc. Announces Data Demonstrates Novel Antimicrobial Activity of AR-12	20/15/20	CI
Arno Therapeutics, Inc. Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer	18/15/18	CI
Arno Therapeutics, Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2015	15/15/15	CI
Arno Therapeutics, Inc. Announces Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12	03/15/03	CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015	16/15/16	CI
Arno Therapeutics, Inc. Announces Promising Data Supporting the Ongoing Clinical Development Program for Lead Compound Onapristone	14/15/14	CI
Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone	07/15/07	CI
Arno Therapeutics, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014	01/15/01	CI
Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014	09/14/09	CI
Arno Therapeutics, Inc. Announces Unaudited Financial Results for the Third Quarter and Nine Months Ended September 30, 2014	15/14/15	CI
Arno Therapeutics Advances Phase I Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors to Expansion Stage	27/14/27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arno Therapeutics, Inc.

Equities

ARNI

US0425642032

Highlights

Filters